145 related articles for article (PubMed ID: 28962586)
1. Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.
Bergstra SA; Olivas O; Akdemir G; Riyazi N; Collée G; van Groenendael JHLM; Landewé RBM; Allaart CF
Arthritis Res Ther; 2017 Sep; 19(1):220. PubMed ID: 28962586
[TBL] [Abstract][Full Text] [Related]
2. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).
Heimans L; Akdemir G; Boer KV; Goekoop-Ruiterman YP; Molenaar ET; van Groenendael JH; Peeters AJ; Steup-Beekman GM; Lard LR; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Arthritis Res Ther; 2016 Jan; 18():23. PubMed ID: 26794605
[TBL] [Abstract][Full Text] [Related]
3. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
[TBL] [Abstract][Full Text] [Related]
4. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study.
Heimans L; Wevers-de Boer KV; Koudijs KK; Visser K; Goekoop-Ruiterman YP; Harbers JB; Steup-Beekman GM; Lard LR; Grillet BA; Huizinga TW; Allaart CF
Arthritis Res Ther; 2013 Oct; 15(5):R173. PubMed ID: 24517212
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
7. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study).
Wevers-de Boer K; Visser K; Heimans L; Ronday HK; Molenaar E; Groenendael JH; Peeters AJ; Westedt ML; Collée G; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Ann Rheum Dis; 2012 Sep; 71(9):1472-7. PubMed ID: 22402145
[TBL] [Abstract][Full Text] [Related]
8. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
Bergstra SA; Landewé RBM; Huizinga TWJ; Allaart CF
Rheumatology (Oxford); 2017 Oct; 56(10):1721-1728. PubMed ID: 28957556
[TBL] [Abstract][Full Text] [Related]
10. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis.
van den Broek M; Lems WF; Allaart CF
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S35-8. PubMed ID: 23078756
[TBL] [Abstract][Full Text] [Related]
11. Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment.
Wevers-de Boer KV; Heimans L; Visser K; Schouffoer AA; Molenaar ET; van Groenendael JH; Peeters AJ; Speyer I; Collée G; Huizinga TW; Allaart CF
Rheumatology (Oxford); 2015 Aug; 54(8):1380-4. PubMed ID: 25687553
[TBL] [Abstract][Full Text] [Related]
12. Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care.
Burgers LE; van der Pol JA; Huizinga TWJ; Allaart CF; van der Helm-van Mil AHM
Arthritis Res Ther; 2019 May; 21(1):115. PubMed ID: 31064384
[TBL] [Abstract][Full Text] [Related]
13. Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.
de Moel EC; Derksen VFAM; Stoeken G; Trouw LA; Bang H; Goekoop RJ; Speyer I; Huizinga TWJ; Allaart CF; Toes REM; van der Woude D
Arthritis Res Ther; 2018 Feb; 20(1):33. PubMed ID: 29482627
[TBL] [Abstract][Full Text] [Related]
14. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
van der Kooij SM; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Güler-Yüksel M; Zwinderman AH; Kerstens PJ; van der Lubbe PA; de Beus WM; Grillet BA; Ronday HK; Huizinga TW; Breedveld FC; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2009 Jun; 68(6):914-21. PubMed ID: 18662933
[TBL] [Abstract][Full Text] [Related]
15. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
16. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
Fanouriakis A; Papalopoulos I; Gergianaki I; Spyrou G; Erden A; Rapsomaniki P; Terizaki M; Avgoustidis N; Repa A; Kougkas N; Bertsias G; Boumpas DT; Sidiropoulos PI
Clin Exp Rheumatol; 2018; 36(5):806-813. PubMed ID: 29533750
[TBL] [Abstract][Full Text] [Related]
17. Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.
Besselink NJ; Westgeest AAA; Klaasen R; Gamala M; van Woerkom JM; Tekstra J; Verhoeven MMA; Van Spil WE; Lafeber FPJG; Marijnissen ACA; Van Laar JM; Jacobs JWG
Trials; 2019 Apr; 20(1):226. PubMed ID: 30999969
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.
Markusse IM; Akdemir G; Dirven L; Goekoop-Ruiterman YP; van Groenendael JH; Han KH; Molenaar TH; Le Cessie S; Lems WF; van der Lubbe PA; Kerstens PJ; Peeters AJ; Ronday HK; de Sonnaville PB; Speyer I; Stijnen T; Ten Wolde S; Huizinga TW; Allaart CF
Ann Intern Med; 2016 Apr; 164(8):523-31. PubMed ID: 27089068
[TBL] [Abstract][Full Text] [Related]
19. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
Klarenbeek NB; Güler-Yüksel M; van der Kooij SM; Han KH; Ronday HK; Kerstens PJ; Seys PE; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2011 Jun; 70(6):1039-46. PubMed ID: 21415052
[TBL] [Abstract][Full Text] [Related]
20. In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols.
Balduzzi S; Scirè CA; Sakellariou G; Benaglio F; Bugatti S; Montecucco C; Caporali R
Clin Exp Rheumatol; 2017; 35(3):401-405. PubMed ID: 27974097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
